Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, TechCrunch reported on July 20 -- a dramatic step-up from the roughly $10 billion valuation the company carried in its most recent prior round. If it closes anywhere near that range, Colossal would rank among the most valuable private biotech companies in the world, a striking outcome for a company best known publicly for headline-grabbing de-extinction projects like its dire wolf and woolly mammoth programs.
Colossal's pitch to investors has shifted over its life: it started as a de-extinction company built around Harvard geneticist George Church's research, and has increasingly repositioned itself as a broader computational-genomics and genetic-engineering platform, with applications in conservation biology, biodiversity preservation and potentially therapeutic gene editing. That platform framing is what's letting the company argue for a valuation multiple more typical of AI infrastructure companies than of a genetics research lab.
“A $20-30 billion valuation would be underwriting the platform thesis and Colossal's brand recognition as much as any specific near-term revenue line.”
The competitive landscape for a company at this scale gets unusual fast -- Colossal isn't cleanly comparable to gene-editing therapeutics companies like Intellia or Editas, nor to synthetic biology platforms like Ginkgo Bioworks, because its actual commercial model (a mix of conservation partnerships, licensing, and de-extinction IP) is still relatively unproven at scale. A $20-30 billion valuation would be underwriting the platform thesis and Colossal's brand recognition as much as any specific near-term revenue line.
The timing lines up with a broader capital rotation toward computational-biology and science-plus-compute investing -- the same thesis behind Dimension Capital's newly closed $800 million third fund. Genomics and biology research increasingly rely on the same GPU-heavy compute infrastructure as AI labs, and investors are increasingly willing to underwrite biotech platform companies using AI-infrastructure-style valuation multiples rather than traditional biotech comps.
For biotech-focused LPs, a valuation step-up this large this fast is worth real scrutiny -- Colossal's public visibility and media attention are genuine assets, but a 2-3x valuation jump in roughly a year raises the bar on what specific commercial or scientific milestones justify it, versus riding a broader wave of enthusiasm for anything positioned at the intersection of biology and compute.